



New Discoveries in Drug Targets and Delivery for Alzheimer's Disease

Guest Editors:

Dr. Elena Puris

Department of Pharmaceutical
Technology and Biopharmacy,
Institute of Pharmacy and
Molecular Biotechnology,
University of Heidelberg, Im
Neuenheimer Feld 329, D-69120
Heidelberg, Germany

Dr. Sabrina Petralla

Department of Pharmaceutical
Technology and Biopharmacy,
Institute of Pharmacy and
Molecular Biotechnology,
University of Heidelberg, Im
Neuenheimer Feld 329, D-69120
Heidelberg, Germany

Deadline for manuscript
submissions:

30 October 2024

Message from the Guest Editors

Dear Colleagues,

Alzheimer's Disease, the most common cause of dementia, affects over 40 million people worldwide. The situation is expected to intensify in the coming years, with devastating social and economic effects. Despite intensive clinical research efforts, there are currently no treatments or effective preventive strategies for AD. In fact, FDA-approved drugs only relieve symptoms. The main reasons for AD treatment's failure are the multifactorial and heterogeneous physiopathological mechanisms of the disease, erroneous selection of drug targets, lack of relevant animal models, and obstacles in drug delivery into the brain due to the high selectivity of the blood–brain barrier, which limits the access of therapeutic agents into the central nervous system.

Therefore, this Special Issue aims to collect original research articles and reviews with the most relevant and innovative findings in the field of AD. Manuscripts dealing with new targets and therapeutic strategies, pharmaceutical formulations, and drug delivery systems as well as relevant models used for the development of effective AD treatments are of great interest.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma